| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06982521 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for… |
Trial sites expanded: 158 -> 192 locations |
| 2026-06-02 | NCT05039801 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid… |
date change Primary completion pushed: 2026-05-29 -> 2028-03-30 |
| 2026-06-02 | NCT05039801 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid… |
date change Completion pushed: 2026-05-29 -> 2028-06-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07281833 | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of… | Breast Cancer | Recruiting |
| NCT04862663 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer… | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Recruiting |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for… | PIK3CA Mutation | Recruiting |
| NCT06635447 | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic… | Breast Cancer | Active, Not Recruiting |
| NCT06764186 | A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in… | Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT04305496 | Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced… | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT04493853 | Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive… | Hormone-Sensitive Prostate Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05593497 | A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide… | High-Risk Prostate Cancer | Recruiting |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients… | Intracranial Meningioma | Recruiting |
| NCT05826964 | Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for… | Breast Cancer | Active, Not Recruiting |
| NCT07426822 | Rash & Diarrhea Prophylaxis With Capivasertib | Metastatic HR+/HER2- Breast Cancer | Not Yet Recruiting |
| NCT04439123 | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes… | Advanced Lymphoma | Active, Not Recruiting |
| NCT03660826 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib… | Endometrial Adenocarcinoma | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various… | Breast Cancer | Recruiting |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in… | Pediatric Cancer | Recruiting |
| NCT07294677 | CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL | Leukemia | Recruiting |
| NCT07287917 | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid… | Melanoma (Skin Cancer) | Recruiting |
| NCT03742102 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast… | Triple Negative Breast Neoplasms | Active, Not Recruiting |
| Phase 1 | |||
| NCT07241065 | A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral… | Healthy Participants | Recruiting |
| NCT07343960 | A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in… | Moderate Hepatic Impairment | Recruiting |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid… | Advanced Endometrial Carcinoma | Recruiting |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial… | BRCA1 Mutation Carrier | Active, Not Recruiting |